Johnson & Johnson Vision announced today that it received FDA approval for its Acuvue Abiliti overnight therapeutic lenses.
Jacksonville, Fla.-based J&J Vision touts the Acuvue Abiliti as the first and only FDA-approved orthokeratology (ortho-k) contact lens for managing myopia, according to a news release.
The company designed the Abiliti overnight ortho-k lenses to be fitted to match the eye based on its unique corneal shape and temporarily reshape the cornea. The technology uses corneal topography, refractive error and other measurements connected to the fitting software, which is user-friendly and provides a precise measurement of the corneal shape while accurately guiding the eye care professional through the fitting process.
Abiliti overnight lenses will be available in two forms — basic overnight therapeutic lenses and overnight therapeutic lenses for astigmatism, J&J Vision said. The company expects the lenses to be available in the U.S. by the end of 2021.
“The FDA approval of Abiliti™ Overnight marks an important milestone in our commitment to help change the trajectory of eye health and reshape the future of children with myopia,” J&J Vision global head of R&D Dr. Xiao-Yu Song said in the release. “We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti™ Overnight Therapeutic Lenses, and continuing with additional products and services to address the progression of myopia.”